Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
Abstract This study assessed the clinical risk factors for periorbital dermatitis (PD) after using dorzolamide/timolol eye drops in a total of 1282 glaucoma patients. Both the PD(+) group and the PD(−) group were evaluated using clinical data such as age, sex, dosing duration, presence of benzalkoni...
Enregistré dans:
Auteurs principaux: | Myungjin Kim, Hyoju Jang, Seungsoo Rho |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e3f88d173aec4c2baf3a503b9d1d7a25 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
par: Inoue K, et autres
Publié: (2015) -
Allergic contact dermatitis caused by dorzolamide eyedrops
par: Lee SJ, et autres
Publié: (2015) -
Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
par: Miguel A Teus, et autres
Publié: (2009) -
Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
par: Sanseau A, et autres
Publié: (2013) -
Effect of dorzolamide/timolol combination on the visual field in glaucoma
par: Takeda S, et autres
Publié: (2014)